NOVARTIS AG;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;L'UNIVERSITÉ MONTPELLIER II
发明人:
申请号：
EP04075926.8
公开号：
EP1431304B1
申请日:
1999.08.10
申请国别(地区):
EP
年份:
2014
代理人:
摘要：
The present invention provides the use of an effective amount of a beta -L-2'-deoxynucleoside of the formula: <；CHEM>； or a pharmaceutically acceptable salt or prodrug thereof, wherein R is selected from the group consisting of H, -CO-alkyl, -CO-aryl, -CO-alkoxyalkyl, -CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate or a stabilized nucleotide； in the manufacture of a medicament for the treatment of a hepatitis B virus infection in a host； the use of an effective amount of a beta -L-2'-deoxynucleoside of the formula: <；CHEM>； or a pharmaceutically acceptable salt or prodrug thereof, wherein R is selected from the group consisting of H, -CO-alkyl, -CO-aryl, -CO-alkoxyalkyl, -CO-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate or a stabilized nucleotide； in the manufacture of a medicament for the treatment of a hepatitis B virus infection in a host； and the use of a combination of the above beta -L-2'-deoxynucleosides in the manufacture of a medicament for the treatment of a hepatitis B virus infection in a host.
